Edwards Lifesciences Corp: directors' dealings · United States · SEC (Form 4)

About Edwards Lifesciences Corp

Edwards Lifesciences Corp. (ticker: EW) is a leading U.S. medical technology company listed on the NYSE in the United States. For French-speaking investors, it stands out as a highly focused cardiovascular medtech platform, with a business model centered primarily on structural heart disease. The company’s roots date back to 1958, when Miles “Lowell” Edwards set out to develop the first artificial heart. The modern company emerged from Edwards Laboratories and later became an independent public company in 2000 following its spin-off from Baxter International. Edwards is headquartered in Irvine, California, which remains an important part of its innovation and engineering identity. The company’s core business is organized around three major pillars. The first is transcatheter aortic valve replacement, or TAVR/TAVI, anchored by the SAPIEN franchise, which has become one of the most established names in aortic valve therapy worldwide. The second is transcatheter mitral and tricuspid therapies, or TMTT, a younger but strategically critical growth area as Edwards extends its reach beyond the aortic valve into more complex structural heart procedures. The third pillar is surgical structural heart, which includes tissue heart valves and related products used in complex cardiac surgery. This concentrated portfolio gives Edwards a strong clinical identity and positions the company as a specialized innovator rather than a broad-based medtech conglomerate. From a competitive standpoint, Edwards is widely regarded as a global leader in several structural heart categories, but it operates in a field with serious rivals, including Medtronic and Abbott. Its moat is based on clinical evidence, physician relationships, product innovation, and the breadth of its valve technology platform. The company distributes its products internationally and serves clinicians in nearly 100 countries, giving it meaningful geographic diversification even though the United States remains a key revenue and development market. Recent news has reinforced the investment case. In late 2025, Edwards received FDA approval for SAPIEN M3, which it described as the first transseptal transcatheter therapy approved in the U.S. for mitral regurgitation. In early 2026, management reported strong full-year 2025 results, highlighted double-digit sales growth, and increased confidence in the 2026 outlook. The company has also been active on capital allocation, including share repurchases, and announced a CFO appointment in May 2026. Overall, EW is best viewed as a premium U.S. healthcare growth stock on the NYSE, supported by a deep structural heart franchise, a strong innovation pipeline, and continued expansion into adjacent valve therapies.